Oncocross Co., Ltd. (KOSDAQ:382150)

Market Cap	135.25B
Revenue (ttm)	1.07B
Net Income (ttm)	-7.26B
Shares Out	11.95M
EPS (ttm)	-670.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	128,015
Average Volume	190,578
Open	11,560
Previous Close	11,480
Day's Range	11,120 - 11,600
52-Week Range	6,260 - 16,700
Beta	n/a
RSI	46.58
Earnings Date	Aug 12, 2025

About Oncocross

Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular D...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 382150

Financial Performance

In 2024, Oncocross's revenue was 1.07 billion, an increase of 1071.49% compared to the previous year's 91.52 million. Losses were -6.48 billion, 53.8% more than in 2023.